RE: SNG “making great strides” NOV v SNG5 Aug 2020 16:58
Reporting is a bit inaccurate saying in development since 2018 and the sp is 38p lol
Synairgen (LON:SNG), another stock we have been following closely, has been making great strides with the development of what is now being termed SNG001, an inhaled formula designed to help treat the symptoms of COVID. Unlike Novacyt, which is focused on the difficult field of testing, Synairgen is seeking to aid patients with the virus, and save them from potentially requiring a ventilator.
This could be critical for survival chances, as anecdotal evidence gathered by The Armchair Trader from medical professionals in the UK, indicates that the survival rate for ventilated patients is not very good at all.
Synairgen reported positive results last month for its Phase II trial which used existing hospitalised patients. Its drug has demonstrated very significant success in helping breathing in patients with COVID. All patients in the study who used the treatment survived, although sadly this was not the case with patients using the placebo.
The inhaled treatment uses interferon beta, a naturally occurring antiviral protein, which supports the lung’s efforts to neutralise the virus. This product has actually been in development since 2018, but is not achieving more significance in the light of the current outbreak. However, there is still plenty more testing to do.
Synairgen shares have enjoyed similar massive success to Novacyt. Unlike Novacyt, they are currently not far off a high of GBX 51, but have slipped in recent days to trade at GBX 38.
Sign In
Follow the stocks
